PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting
04 Mar 2022
LatanoprostGlaucoma
PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle Glaucoma (POAG) will be presented at the 2022 American Glaucoma Society (AGS) Annual Meeting. The conference is taking place March 3-6, 2022 in Nashville, TN.
The accepted poster, "Interim Phase 2a Clinical Study Results with PA5108 Latanoprost Ocular Implant for the Treatment of Glaucoma" will be presented by Associate Professor Michael Coote, MD, a leading glaucoma specialist at Melbourne Eye Specialists and a principal investigator of the study. The poster will be available to view on the Virtual Meeting Platform throughout the meeting.
The open-label, multicenter, Phase IIa study met both its primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort, demonstrating a potential significant benefit of the PA5108 Ocular Implant with the proprietary Prezia™ Sustained Drug Delivery Technology designed to treat patients with glaucoma by enabling a constant dose of medication via a safe and effective biodegradable implant. Results of the study were previewed at last month's 11th Annual Glaucoma 360 New Horizons Forum in San Francisco, CA.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.